相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells
Julie Giraud et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Expression of long noncoding RNAs in cancer-associated fibroblasts linked to patient survival in ovarian cancer
Emily K. Colvin et al.
CANCER SCIENCE (2020)
The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer
Anais Wambecke et al.
GYNECOLOGIC ONCOLOGY (2020)
Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer
Cecilie Abildgaard et al.
FRONTIERS IN ONCOLOGY (2020)
Back to the Future: Rethinking the Great Potential of lncRNASfor Optimizing Chemotherapeutic Response in Ovarian Cancer
Abdelrahman M. Elsayed et al.
CANCERS (2020)
Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers
Na Gao et al.
FRONTIERS IN ONCOLOGY (2020)
Downregulation of LINC00515 in high-grade serous ovarian cancer and its relationship with platinum resistance
Mao-Wei Ni et al.
BIOMARKERS IN MEDICINE (2019)
Aberrant activation of CYR61 enhancers in colorectal cancer development
Lingzhu Xie et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Analysis of the role of the Hippo pathway in cancer
Yanyan Han
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Long Non-Coding RNA in the Pathogenesis of Cancers
Yujing Chi et al.
CELLS (2019)
Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer
Jing He et al.
BMC MOLECULAR AND CELL BIOLOGY (2019)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Crosstalk between the Notch signaling pathway and long non-coding RNAs
Andreas Reicher et al.
CANCER LETTERS (2018)
Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway
Liang Dong et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2018)
Paracrine and epigenetic control of CAF-induced metastasis: the role of HOTAIR stimulated by TGF-beta 1 secretion
Yu Ren et al.
MOLECULAR CANCER (2018)
Hippo signaling dysfunction induces cancer cell addiction to YAP
Han Han et al.
ONCOGENE (2018)
lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells
Peide Huang et al.
SCIENTIFIC REPORTS (2018)
Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics
Charles T. Foster et al.
GENES & DEVELOPMENT (2017)
Hippo pathway mediates resistance to cytotoxic drugs
Taranjit S. Gujral et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Verteporfin inhibits growth of human glioma in vitro without light activation
Ahmad Al-Moujahed et al.
SCIENTIFIC REPORTS (2017)
Long Noncoding RNA and Cancer: A New Paradigm
Arunoday Bhan et al.
CANCER RESEARCH (2017)
Platinum-based drugs: past, present and future
Shahana Dilruba et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients
Yan Xia et al.
PLOS ONE (2014)
Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts
Fernando Calvo et al.
NATURE CELL BIOLOGY (2013)
Landscape of transcription in human cells
Sarah Djebali et al.
NATURE (2012)
The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene
X. Zhang et al.
ONCOGENE (2011)
Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene
Chad A. Hall et al.
CANCER RESEARCH (2010)
Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapies
Kathleen M. Darcy et al.
GYNECOLOGIC ONCOLOGY (2010)
Stromal Compartment as a Survival Prognostic Factor in Advanced Ovarian Carcinoma
Alexandre Labiche et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis
Kosuke Yoshihara et al.
CANCER SCIENCE (2009)
Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer
Franco Muggia
GYNECOLOGIC ONCOLOGY (2009)
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer
JB Welsh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
